Endocyte raises $26 million in Series C funding

Oct 16, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Company: Medical Ventures Corp (MVTRF)

Endocyte, Inc., a cancer drug discovery and development company, has secured $26 million in Series C funding from Clarian Health Ventures, Inc., Sanderling Ventures, Burrill & Company, American Bailey Ventures, Blue Chip Venture Company and Triathlon Medical Ventures.

Deal Type    Venture Finance
Sub-Category None
Deal Status  Completed: 2009-10-16

Deal Participants

Target (Company) Endocyte, Inc.

News Provided by COMTEX

Company: Medical Ventures Corp (MVTRF)

Related terms: blue chip, cancer, health

Cancer drug developer Endocyte extends series C, reins in $26m
Oct 19, 2009
...participation from all existing investors, including Sanderling Ventures, Burrill & Co, American Bailey Ventures, Blue Chip Venture Co, and Triathlon Medical Ventures. Clarian Health Ventures also participated as a new investor. Based...

Smart Sourcing Summit: Expect "solid" recovery
Oct 14, 2009
...Summit this week in Chicago, Johnson projects a 3.9% growth in gross domestic product (GDP) in 2010. The consensus Blue Chip Economic Indicators forecast for 2010 GDP growth is 2.4%. "I have the view of solid GDP growth ahead in 2010 because...

Endocyte Officials Announce Close of $26 Million Equity Financing - Zibb.com
Oct 16, 2009
...Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co., and Triathlon Medical Ventures. Clarian Health Ventures also...org Related terms: biotechnology, blue chip, cancer, clinical, disease, drugs...

Tachographs Directory: Page 1
10 hours 31 minutes ago
...at TruTac, have been providing products and services for over 10 years to the road haulage industry. Working with over 250 blue chip clients within the retailing, ind... More about TruTac The Viscount Centre University of Warwick Science Park...

Sponsored Links

Endocyte raises $26 million in Series C funding

Related Articles